GFM
CRVS icon

GF Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

GF Fund Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1K Buy
1,750
+83
+5% +$1.15K ﹤0.01% 457
2026
Q1 		$24.4K Buy
1,667
+201
+14% +$3.21K ﹤0.01% 475
2025
Q4 		$11.3K Sell
1,466
-137
-9% -$1.08K ﹤0.01% 564
2025
Q3 		$11.8K Buy
1,603
+9
+0.6% +$46 ﹤0.01% 540
2025
Q2 		$6.38K Hold
1,594
– – ﹤0.01% 612
2025
Q1 		$5.07K Buy
1,594
+245
+18% +$1.15K ﹤0.01% 623
2024
Q4 		$7.22K Buy
+1,349
New +$10.1K ﹤0.01% 584

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

GF Fund Management's CRVS Position: Q2 2026 in Review

GF Fund Management increased its Corvus Pharmaceuticals (CRVS) stake by 5% in Q2 2026, buying an estimated $1.15K and bringing the position to 1,750 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #457.

GF Fund Management first reported a position in CRVS in Q4 2024 and has held it in 7 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • GF Fund Management held 1,750 shares of Corvus Pharmaceuticals worth $26.1K as of Q2 2026.
  • GF Fund Management bought 83 Corvus Pharmaceuticals shares in Q2 2026, an estimated $1.15K.
  • Corvus Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #457 holding.
  • GF Fund Management first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.